ERBITUX PI PDF

ERBITUX PI PDF

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Nakree Shakar
Country: Laos
Language: English (Spanish)
Genre: Politics
Published (Last): 17 May 2017
Pages: 333
PDF File Size: 16.37 Mb
ePub File Size: 15.43 Mb
ISBN: 137-8-40385-313-6
Downloads: 62830
Price: Free* [*Free Regsitration Required]
Uploader: Arakus

Sacituzumab govitecan The risk or severity of adverse effects can be increased when Cetuximab is combined with Sacituzumab govitecan. The risk or severity of adverse effects can be increased when Cetuximab is combined with Ramucirumab. Monitor patients receiving Erbitux for dermatologic toxicities and infectious sequelae.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab. Fanolesomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fanolesomab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Lorvotuzumab mertansine.

Therefore, the improvement in overall activity seen with cetuximab in these studies was accompanied by better maintenance of quality of life. The median survival was ervitux. Fulranumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fulranumab.

Cetuximab in the management of colorectal cancer

The risk or severity of adverse effects can be increased when Cetuximab is combined with Amatuximab. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Cetuximab.

Anti-epidermal growth factor receptor monoclonal antibody upregulates p27 KIP1 and p15 INK4B and induces G1 arrest in oral squamous carcinoma cell lines. The risk or severity of adverse effects can be increased when Efbitux is combined with Onartuzumab.

  74HC4050D DATASHEET PDF

Zeranol Zeranol may increase the thrombogenic activities of Cetuximab.

Secukinumab The risk ebitux severity of adverse effects can be increased when Cetuximab is combined with Secukinumab. Oregovomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Hepatitis B Immune Globulin. Subscribe to receive email notifications whenever new articles are egbitux.

Disruption or depletion of EGFR in animal models results in impairment of embryo-fetal development including effects on placental, lung, cardiac, skin, and neural development see Data. Bavituximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bavituximab.

EGFR-dependent transcriptional programs are also affected by cetuximab, which reduces angiogenesis, tumor invasiveness, and metastatic spread Harding and Burtness Results of the planned PFS drbitux ORR analysis in all randomized patients and post-hoc PFS and ORR analysis in subgroups of patients defined by K-Ras mutation status, and post-hoc analysis of updated Srbitux based on additional follow-up events in all randomized patients and in subgroups of patients defined by K-Ras mutation status are presented in Table 8 and Figure 2.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab. Moxestrol Moxestrol may increase the thrombogenic activities of Cetuximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin. A total of patients were enrolled; 89 patients were randomized to the study protocol, and the remaining 77 patients who were ineligible for randomization mostly due to the presence of grade 2 or greater skin toxicity after the first 3 weeks were followed on the standard regimen Van Cutsem et al The risk or severity of adverse effects can be increased when Cetuximab is combined with Reslizumab.

  BETA THALASSEMIE MAJEURE PDF

Cetuximab binds to the epidermal growth factor receptor EGFr on both normal and tumor cells. The risk or severity of adverse effects can be increased when Cetuximab is combined with Patritumab. The efbitux or severity of adverse effects can be increased when Cetuximab is combined with Sibrotuzumab.

Fontolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fontolizumab.

TGA eBS – Product and Consumer Medicine Information

Additionally, this study will explore which regimen is most likely to allow patients to undergo potentially curative surgery of metastases following chemotherapy. The risk or severity of adverse effects can be increased when Cetuximab erbitus combined with Trastuzumab emtansine.

Belimumab The risk eribtux severity of adverse effects can be increased when Cetuximab is combined with Belimumab. Plozalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Plozalizumab.

Erbitux can cause interstitial lung disease ILD. In combination with radiation therapy or platinum-based therapy and fluorouracil.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Emibetuzumab. Denosumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Denosumab.

Cunningham et al b.